Renal damage in primary aldosteronism: Results of the PAPY study

Hypertension

Volumn 48, Issue 2, 2006, Pages 232-238

  Rossi, Gian Paolo ^a   Bernini, Giampaolo ^a   Desideri, Giovambattista ^a   Fabris, Bruno ^a   Ferri, Claudio ^a   Giacchetti, Gilberta ^a   Letizia, Claudio ^a   Maccario, Mauro ^a   Mannelli, Massimo ^a   Matterello, Mee Jung ^a   Montemurro, Domenico ^a   Palumbo, Gaetana ^a   Rizzoni, Damiano ^a   Rossi, Ermanno ^a   Pessina, Achille Cesare ^a   Mantero, Franco ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Adrenal gland; Aldosterone; Hypertension, endocrine; Hypertrophy; Kidney; Mineralocorticoids

Indexed keywords

ADRENAL CORTEX ADENOMA; ADULT; ALBUMINURIA; ALDOSTERONE RELEASE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; ENDOCRINE TUMOR; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HUMAN; HYPERTENSION; ITALY; KIDNEY INJURY; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NATRIURESIS; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SCREENING;

ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CAUSALITY; COHORT STUDIES; COMORBIDITY; CREATININE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; ITALY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MIDDLE AGED; POTASSIUM; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RENIN;

EID: 33748174236     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000230444.01215.6a     Document Type: Article

References (45)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005;16:104-107.
4. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on fifth avenue? Curr Hypertens Rep. 2004;6:1-4.
5. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in hypertensive patients. J Am Coll Cardiol. 2006 In press.
6. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10:1-8.
7. Rossi G, Rossi A, Sacchetto A, Pavan E, Pessina AC. Hypertensive cerebrovascular disease and the renin-angiotensin system. Stroke. 1995;26:1700-1706.
8. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
9. Campbell SE, Diaz-Arias AA, Weber KT. Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press. 1992;1:149-156.
10. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Tiberio G, Giulini SM, Rossi GP, Bernini G, Agabiti-Rosei E. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension. 1998;31:335-341.
11. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045.
12. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471-1478.
13. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
14. Rossi GP. Cardiac consequences of aldosterone excess in human hypertension. Am J Hypertens. 2006;19:10-12.
15. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
16. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 1995;13:1801-1802.
17. Ribstein J, du CG, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16:1320-1325.
18. Zelmanovitz T, Gross JL, Oliveira J, de Azevedo MJ. Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. Diabetes Care. 1998;21:1076-1079.
19. Palatini P. Microalbuminuria in hypertension. Curr Hypertens Rep. 2003;5:208-214.
20. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
22. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, Perazzoli F, Pessina AC. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf). 1998;49:713-723.
23. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001;86:1083-1090.
24. Morganti A, Pelizzola D, Mantero F, Gazzano G, Opocher G, Piffanelli A. Immunoradiometric versus enzymatic renin assay: results of the Italian Multicenter Comparative Study. Italian Multicenter Study for Standardization of Renin Measurement. J Hypertens. 1995;13:19-26.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
26. Palatini P, Mormino P, Mos L, Mazzer A, Dorigatti F, Zanata G, Longo D, Garbelotto R, De Toni R, Graniero G, Pessina AC. Microalbuminuria, renal function and development of sustained hypertension: a longitudinal study in the early stage of hypertension. J Hypertens. 2005;23:175-182.
27. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair D, Cole P. Guidelines for the reporting of renal artery revascularization in clinical trials. Am Heart Association. Circulation. 2002;106:1572-1585.
28. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183.
29. Tabachnick BG. Using Multivariate Statistics, 4th ed. Needham Heights, MA: Allyn & Bacon; 2001.
30. Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab. 1997;82:457-460.
31. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40:897-902.
32. Young MJ, Funder JW. Mineralocorticoids, salt, hypertension: effects on the heart. Steroids. 1996;61:233-235.
33. Baldoncini R, Desideri G, Bellini C, Valenti M, De Mattia G, Santucci A, Ferri C. High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patients. Kidney Int. 1999;56:1499-1504.
34. Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone "escape." Hypertension. 1984;6:I183-I192.
35. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14-18.
36. Fioretto P, Stehouwer CD, Mauer M, Chiesura-Corona M, Brocco E, Carraro A, Bortoloso E, van Hinsbergh VW, Crepaldi G, Nosadini R. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia. 1998;41:233-236.
37. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109:2857-2861.
38. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond). 2002;103:425-431.
39. Tobian L, Lange J, Ulm K, Wold L, Iwai J. Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered. Hypertension. 1985;7:I110-I114.
40. Sugimoto T, Tobian L, Ganguli MC. High potassium diets protect against dysfunction of endothelial cells in stroke-prone spontaneously hypertensive rats. Hypertension. 1988;11:579-585.
41. Tobian L, MacNeill D, Johnson MA, Ganguli MC, Iwai J. Potassium protection against lesions of the renal tubules, arteries, and glomeruli and nephron loss in salt-loaded hypertensive Dahl S rats. Hypertension. 1984;6:I170-I176.
42. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab. 2005;16:114-119.
43. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-1050.
44. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42:49-55.
45. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.